Development of Lymphoma in Patients with Sjogren's Syndrome

Nicolas Lloves¹, Anastasia Secco², Marta Mamani³, Silvia Beatriz Papasidero⁴, Cecilia Asnal⁵, Lida Santiago⁶, Paula Pucci⁵ and Soledad Retamozo⁷, ¹Rheumatology Department, Hospital Rivadavia, Buenos Aires, Argentina, ²Rheumatology Section, Hospital Bernardino Rivadavia, CABA, Argentina, ³Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ⁴Rheumatology Section, Hospital General de Agudos Dr. Enrique Tornú, CABA, Argentina, ⁵Rheumatology, Hospital Alemán, Buenos Aires, Argentina, ⁶Hospital Bernardino Rivadavia, Ciudad Autónoma de Buenos Aires, Argentina, ⁷Rheumatology Unit, Hospital Privado Universitario de Córdoba, Institute University of Biomedical Sciences University of Córdoba (IUCBC), Cordoba, Argentina

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Sjogren's syndrome and cancer

Session Information

Date: Monday, October 22, 2018

Title: Sjögren's Syndrome – Basic and Clinical Science Poster

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Non-Hodgkin lymphoma (NHL) is one of the most feared complications of primary Sjogren’s syndrome (pSS). The most frequent is MALT type lymphoma, with localization in the parotid glands being usual. There are no multicentric data in the Argentine population regarding the frequency of appearance of this type of cancer in patients with pSS and the possible predictors for this outcome.
The aim of this study was to describe the prevalence and incidence rate of lymphoma in patients with pSS in nine centers in Argentina. To determine the frequency of commitment of the domains of the baseline clinical ESSDAI in the patients who developed lymphoma in the course of their follow-up and compare it with the rest of the sample.

Methods: To respond to the primary objective, the design will be observational, descriptive and retrospective. To evaluate the predictors of lymphoma development, the design will be observational, analytical, retrospective cohort. We included patients older than 18 years with a diagnosis of pSS according to ACR / EULAR 2002 criteria, included in a multi-center Argentine database. Patients diagnosed with another associated autoimmune rheumatic disease were excluded.

Results: We included 708 patients, 95% female, with a mean age of 54.44 years (SD +/- 13.67), mean age at diagnosis of 49.72 years (SD +/- 13.32) and mean age of onset of symptoms 47.19 (SD +/- 13.03). Fifteen patients presented lymphoma (prevalence: 2.12%). Six hundred thirty-six patients provided information for the survival analysis. The average follow-up time was 5 years (SD +/- 6.5). The incidence rate of lymphoma was 0.47 per 100 patient-years. The median time from the diagnosis of pSS to the development of lymphoma was 4 years (ric: 1-6). The most frequently lymphoma type was MALT. The main predictor of lymphoma development was recurrent parotidomegaly (H.R: 4.17, 95% CI: 1.42-12.22). Table 1 reports the results regarding the clinical ESSDAI.

Conclusion: The prevalence of lymphoma was 2.12% and the incidence rate of 0.47 lymphomas per 100 patients per year. Patients who developed lymphoma had a higher frequency of involvement of most of the domains of the baseline clinical ESSDAI compared to patients who did not present this complication. We found recurrent parotidomegaly as the main predictor of the development of this cancer.

Disclosure: N. Lloves, None; A. Secco, None; M. Mamani, None; S. B. Papasidero, None; C. Asnal, None; L. Santiago, None; P. Pucci, None; S. Retamozo, None.

To cite this abstract in AMA style:

Lloves N, Secco A, Mamani M, Papasidero SB, Asnal C, Santiago L, Pucci P, Retamozo S. Development of Lymphoma in Patients with Sjogren’s Syndrome [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/development-of-lymphoma-in-patients-with-sjogrens-syndrome/. Accessed .

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-of-lymphoma-in-patients-with-sjogrens-syndrome/